Andrew R Branagan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4248212/publications.pdf

Version: 2024-02-01

76 papers	3,831 citations	201674 27 h-index	128289 60 g-index
80 all docs	80 docs citations	80 times ranked	2821 citing authors

#	Article	IF	Citations
1	Natural history of WaldenstrÃ¶m macroglobulinemia following acquired resistance to ibrutinib monotherapy. Haematologica, 2022, 107, 1163-1171.	3.5	11
2	Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia, 2022, 36, 532-539.	7.2	50
3	Venetoclax in Previously Treated WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2022, 40, 63-71.	1.6	53
4	Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematology,the, 2022, 9, e143-e161.	4.6	44
5	Response and survival predictors in a cohort of 319 patients with WaldenstrÃ¶m macroglobulinemia treated with ibrutinib monotherapy. Blood Advances, 2022, 6, 1015-1024.	5.2	12
6	Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma. Cancer, 2022, 128, 1996-2004.	4.1	12
7	SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for WaldenstrÃ¶m Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 547-556.	0.4	6
8	A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas. Blood Advances, 2022, 6, 3332-3338.	5.2	4
9	Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia. Expert Review of Anticancer Therapy, 2022, , .	2.4	3
10	Abstract CT550: Phase II study of acalabrutinib and an anti-CD20 monoclonal antibody in patients with anti-MAG mediated neuropathy. Cancer Research, 2022, 82, CT550-CT550.	0.9	0
11	A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.. Journal of Clinical Oncology, 2022, 40, 8012-8012.	1.6	2
12	Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2021, 39, 565-575.	1.6	98
13	Role of MBD3-SOX2 axis in residual myeloma following pomalidomide. Leukemia, 2021, 35, 3319-3323.	7.2	4
14	Clinical application of genomics in WaldenstrÃ¶m macroglobulinemia. Leukemia and Lymphoma, 2021, 62, 1805-1815.	1.3	3
15	Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias. Blood Advances, 2021, 5, 1535-1539.	5.2	17
16	Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic nextâ€generation sequencing in WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2021, 194, 730-733.	2.5	16
17	Cellâ€free <scp>DNA</scp> analysis for detection of <scp>MYD88^{L265P}</scp> and <scp>CXCR4^{S338X}</scp> mutations in <scp>W</scp>aldenstrÃ¶m macroglobulinemia. American Journal of Hematology, 2021, 96, E250-E253.	4.1	8
18	Perceptions of prognosis in caregivers of multiple myeloma (MM) patients.. Journal of Clinical Oncology, 2021, 39, 12082-12082.	1.6	0

#	Article	IF	Citations
19	Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated WaldenstrÃ¶m macroglobulinemia. Blood, 2021, 138, 1535-1539.	1.4	32
20	Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in WaldenstrÃ¶m Macroglobulinemia. HemaSphere, 2021, 5, e624.	2.7	15
21	Lifestyle considerations in multiple myeloma. Blood Cancer Journal, 2021, 11, 172.	6.2	11
22	Quality of Life, Psychological Distress, and Prognostic Awareness in Patients with Multiple Myeloma. Blood, 2021, 138, 4082-4082.	1.4	0
23	COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and WaldenstrÃ¶m Macroglobulinemia. Blood, 2021, 138, 3801-3801.	1.4	1
24	Pirtobrutinib (LOXO-305) Is Active and Overcomes ERK Related Pro-Survival Signaling in Ibrutinib Resistant, BTK Cys481 Mutant Expressing WM and ABC DLBCL Lymphoma Cells Driven By Activating MYD88 Mutations. Blood, 2021, 138, 2261-2261.	1.4	6
25	Infectious Complications in Patients Treated with Idecabtagene Vicleucel for Relapsed and Refractory Multiple Myeloma. Blood, 2021, 138, 3839-3839.	1.4	3
26	Real-World Observations and Practical Considerations of Subcutaneous Daratumumab Administration in Multiple Myeloma. Blood, 2021, 138, 5018-5018.	1.4	2
27	Quality of Life, Psychological Distress, and Prognostic Awareness in Caregivers of Patients with Multiple Myeloma. Blood, 2021, 138, 3044-3044.	1.4	1
28	Molecular Features and Clinical Outcomes of Extramedullary Plasmacytomas. Blood, 2021, 138, 398-398.	1.4	1
29	Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with WaldenstrÃ¶m's Macroglobulinemia with MYD88 and CXCR4 Mutations. Blood, 2021, 138, 1362-1362.	1.4	8
30	A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma. Blood, 2021, 138, 5043-5043.	1.4	0
31	Consensus Statement on the Management of WaldenstrÃ¶m Macroglobulinemia Patients During the COVIDâ€19ÂPandemic. HemaSphere, 2020, 4, e433.	2.7	11
32	Consensus treatment recommendations from the tenth International Workshop for WaldenstrÃ¶m Macroglobulinaemia. Lancet Haematology,the, 2020, 7, e827-e837.	4.6	96
33	Genomic Landscape of WaldenstrÃ¶m Macroglobulinemia and Its Impact on Treatment Strategies. Journal of Clinical Oncology, 2020, 38, 1198-1208.	1.6	103
34	Current Treatment Strategies for Multiple Myeloma. JCO Oncology Practice, 2020, 16, 5-14.	2.9	28
35	A phase II, single-arm study of denosumab in multiple myeloma patients with renal insufficiency.. Journal of Clinical Oncology, 2020, 38, 8520-8520.	1.6	0
36	Extending Dosing Intervals of Denosumab As a Maintenance Strategy in Multiple Myeloma: A Real-World Experience at a Large Academic Cancer Center. Blood, 2020, 136, 13-13.	1.4	0

#	Article	IF	Citations
37	Updates and rationale of clinical trials in multiple myeloma. Advances in Cell and Gene Therapy, 2019, 2, e59.	0.9	0
38	Genomic landscape of WaldenstrÃ¶m's macroglobulinemia. HemaSphere, 2019, 3, 58-61.	2.7	1
39	Current management and emerging treatment strategies for multiple myeloma. Rinsho Ketsueki/the Japanese Journal of Clinical Hematology, 2019, 60, 1243-1256.	0.5	7
40	A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma. Blood, 2019, 134, 3169-3169.	1.4	6
41	Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 296-304.e2.	0.4	39
42	2168. Journal of Clinical and Translational Science, 2017, 1, 31-32.	0.6	0
43	Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice. Nature Medicine, 2016, 22, 1351-1357.	30.7	132
44	Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma. New England Journal of Medicine, 2016, 374, 555-561.	27.0	167
45	Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical Trial. Blood, 2016, 128, 2139-2139.	1.4	1
46	Niche-Dependent Growth of Malignant and Pre-Neoplastic Plasma Cells in Humanized Mice. Blood, 2015, 126, 120-120.	1.4	1
47	FluzoneÂ® High-Dose Influenza Vaccine with a Booster Is Associated with Low Rates of Influenza Infection in Patients with Plasma Cell Disorders. Blood, 2015, 126, 3058-3058.	1.4	1
48	Lenalidomide and Rituximab in Waldenstrom's Macroglobulinemia. Clinical Cancer Research, 2009, 15, 355-360.	7.0	124
49	Long-term outcomes to fludarabine and rituximab in WaldenstrÃ¶m macroglobulinemia. Blood, 2009, 113, 3673-3678.	1.4	141
50	CD27-CD70 interactions in the pathogenesis of WaldenstrÃ¶m macroglobulinemia. Blood, 2008, 112, 4683-4689.	1.4	74
51	Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood, 2008, 112, 4452-4457.	1.4	135
52	Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248. Clinical Cancer Research, 2007, 13, 3320-3325.	7.0	186
53	Genetic Linkage of FcgÎ³RIIa and FcÎ³RIIIa and Implications for Their Use in Predicting Clinical Responses to CD20-Directed Monoclonal Antibody Therapy. Clinical Lymphoma and Myeloma, 2007, 7, 286-290.	1.4	30
54	Novel Agents in the Treatment of WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2007, 7, S199-S206.	1.4	15

#	Article	IF	Citations
55	Hepatitis C viral infection is not associated with WaldenstrÃ¶m's macroglobulinemia. American Journal of Hematology, 2007, 82, 83-84.	4.1	64
56	Establishment of BCWM.1 cell line for WaldenstrÃ¶m's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Experimental Hematology, 2007, 35, 1366-1375.	0.4	61
57	CD52 Is Expressed on Human Mast Cells and Is a Potential Therapeutic Target in WaldenstrÃ¶m's Macroglobulinemia and Mast Cell Disorders. Clinical Lymphoma and Myeloma, 2006, 6, 478-483.	1.4	41
58	Polymorphisms in FcÎ³RIIIA (CD16) Receptor Expression Are Associated With Clinical Response to Rituximab in WaldenstrÃ¶mâ€™s Macroglobulinemia. Journal of Clinical Oncology, 2005, 23, 474-481.	1.6	263
59	CD5, CD10, and CD23 Expression in WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2005, 5, 246-249.	2.1	71
60	CHOP plus Rituximab Therapy in WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2005, 5, 273-277.	2.1	55
61	Abnormal Expression of the Plasma Cell Differentiation Factor X-Box Protein 1 (Xbp-1) in Waldenstromâ€™s Macroglobulinemia.. Blood, 2005, 106, 1003-1003.	1.4	2
62	Phase II Study of CC-5013 (Revlimid) and Rituximab in WaldenstroÌˆmâ€™s Macroglobulinemia: Preliminary Safety and Efficacy Results.. Blood, 2005, 106, 2443-2443.	1.4	7
63	A Novel Functional Role for Soluble CD27 in the Pathogenesis of Waldenstromâ€™s Macroglobulinemia.. Blood, 2005, 106, 4701-4701.	1.4	6
64	Establishment of a Waldenstromâ€™s Macroglobulinemia Cell Line (BCWM.1) with Productive In Vivo Engraftment in SCID-hu Mice.. Blood, 2005, 106, 979-979.	1.4	5
65	Bone Marrow Mast Cells Are Significantly Increased in Patients with Waldenstromâ€™s Macroglobulinemia, and Their Number Following Therapeutic Intervention Is Dependent on Extent of Response.. Blood, 2005, 106, 980-980.	1.4	3
66	Clinical Responses to Sildenafil in Waldenstrom's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2004, 5, 205-207.	2.1	26
67	B-Lymphocyte Stimulator Protein (BLYS) Is Expressed by Bone Marrow Mast and Lymphoplasmacytic Cells in Waldenstromâ€™s Macroglobulinemia, and Provides Signaling for Growth, Survival and IgM Secretion.. Blood, 2004, 104, 3358-3358.	1.4	13
68	High Levels of Soluble Immunoregulatory Receptors in Patients with WaldenstroÌˆMâ€™s Macroglobulinemia.. Blood, 2004, 104, 4881-4881.	1.4	4
69	Vascular Endothelial Growth Factor (VEGF) Is a Growth and Survival Factor in Waldenstromâ€™s Macroglobulinemia.. Blood, 2004, 104, 4892-4892.	1.4	2
70	IgA and IgG Hypogammaglobulinemia Persists in Most Patients with Waldenstromâ€™s Macroglobulinemia Despite Therapeutic Responses, Including Complete Remissions.. Blood, 2004, 104, 4896-4896.	1.4	5
71	Campath-1H in WaldenstroÌˆmâ€™s Macroglobulinemia.. Blood, 2004, 104, 4924-4924.	1.4	4
72	Lymphoplasmacytic Cells and Mast Cells Are Targets for Imatinib Mesylate (Gleevec, Glivec) in Waldenstromâ€™s Macroglobulinemia.. Blood, 2004, 104, 4929-4929.	1.4	2

#	Article	IF	Citations
73	Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 2003, 30, 127-131.	2.2	86
74	Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 2003, 30, 116-120.	2.2	304
75	Treatment recommendations in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 2003, 30, 121-126.	2.2	94
76	Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 2003, 30, 110-115.	2.2	841